Susquehanna Fundamental Investments LLC Purchases New Holdings in Zymeworks Inc. (NYSE:ZYME)

Susquehanna Fundamental Investments LLC purchased a new position in Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 97,553 shares of the company's stock, valued at approximately $1,428,000. Susquehanna Fundamental Investments LLC owned approximately 0.14% of Zymeworks as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Walleye Capital LLC purchased a new position in shares of Zymeworks during the fourth quarter worth $6,629,000. Schroder Investment Management Group acquired a new position in shares of Zymeworks in the 4th quarter valued at about $4,892,000. Assenagon Asset Management S.A. boosted its stake in shares of Zymeworks by 93.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after buying an additional 311,107 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in Zymeworks during the fourth quarter worth about $3,368,000. Finally, Norges Bank acquired a new position in Zymeworks in the fourth quarter valued at approximately $2,953,000. Hedge funds and other institutional investors own 92.89% of the company's stock.

Analysts Set New Price Targets

ZYME has been the subject of several research analyst reports. Lifesci Capital began coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price target for the company. Citigroup increased their price objective on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, March 7th. Finally, HC Wainwright boosted their target price on Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Monday, March 10th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.

Zymeworks Stock Down 3.7 %

Shares of NYSE ZYME traded down $0.48 during mid-day trading on Tuesday, hitting $12.37. 72,768 shares of the company were exchanged, compared to its average volume of 608,683. The stock has a 50 day simple moving average of $11.99 and a 200-day simple moving average of $13.50. The firm has a market cap of $860.95 million, a price-to-earnings ratio of -8.28 and a beta of 1.24. Zymeworks Inc. has a 1-year low of $8.21 and a 1-year high of $17.70.

Insider Buying and Selling at Zymeworks

In other news, Director Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock in a transaction that occurred on Tuesday, March 11th. The shares were purchased at an average price of $11.49 per share, for a total transaction of $3,684,728.10. Following the completion of the acquisition, the director now owns 16,040,851 shares of the company's stock, valued at $184,309,377.99. The trade was a 2.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders acquired 1,350,347 shares of company stock worth $16,137,499. Insiders own 1.92% of the company's stock.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.